GA2LEN (Global Allergy and Asthma European Network): European network of excellence for asthma and allergic diseases;GA2LEN (Global Allergy and Asthma European Network): Network di eccellenza europeo per l'asma e le malattie allergiche

Minerva Medica

Volumn 100, Issue 6, 2009, Pages 525-534

  Gjomarkaj, M ^a   Pace, E ^a   Canonica, G W ^b   Bonini, S ^c   Ricci, G ^d   Burney, P ^e   Zuberbier, T ^f   Van Cauwenberge, P ^g   Bousquet, J ^h  

^a CNR   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g GHENT UNIVERSITY   (Belgium)

^h INSERM   (France)

Author keywords

Allergy; Asthma; Guidelines

Indexed keywords

ALLERGIC ASTHMA; CLINICAL FEATURE; DISEASE SEVERITY; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; MEDICAL RESEARCH; MOTIVATION; REVIEW; ASTHMA; EUROPEAN UNION; GENETICS; HEALTH CARE FACILITY; HUMAN; HYPERSENSITIVITY; INTERNATIONAL COOPERATION; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PROGRAM DEVELOPMENT; RESEARCH; STANDARD;

ASTHMA; EUROPEAN UNION; HUMANS; HYPERSENSITIVITY; INTERNATIONAL COOPERATION; ORGANIZATIONAL OBJECTIVES; PRACTICE GUIDELINES AS TOPIC; PROGRAM DEVELOPMENT; RESEARCH; TISSUE BANKS;

EID: 77949832401     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Bousquet J, Khaltaev N. Global surveillance, prevention and control of chronic respiratory diseases. A comprehensive approach. Global Alliance against Chronic Respiratory Diseases. Geneve: World Health Organization; 2007.
2. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl):S147-334.
3. 2)LEN and AllerGen). Allergy 2008;63(Suppl 86)8-60.
4. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007;120:381-7.
5. Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008;372:1049-57.
6. Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asdima. Allergy 2008;63:670-84.
7. Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006;117:158-62.
8. Bousquet J, Demarteau N, Mullol J, van den Akkervan Marie ME, Van Ganse E, Bachert C. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 2005;60:788-94.
9. *Zuberbier T, Lötvall J. Allergies have a socio-economic impact. Proceedings of the Annual Meeting of the European Academy of Allergology and Clinical Immunology; 2008 June; Barcelona. Allergy 2008;(Suppl 84).
10. WHO. 2008-2013 Action plan for the global strategy for the prevention and control of non communicable diseases. Prevent and control cardiovascular diseases, cancers, chronic respiratory diseases, diabetes, [cited 2009 November 24]. Available at: http://wwwwhoint/nmh/Actionplan-PC-NCD-2008pdf. 2008.
11. *Bousquet J, Bieber T, Fokkens W, Kowalski ML, Humbert M, Niggemann B et al. Important questions in allergy: novel research areas. Allergy 2008;63:143-7.
12. 2LEN paper. Allergy 2008;63:842-53.
13. *Demoly P, Pichler W, Pirmohamed M, Romano A. Important questions in allergy: 1drug/allergy/hypersensitivity. Allergy 2008;63:616-9.
14. *Bachert C, Van Bruaene N, Toskala E, Zhang N, Olze H, Scadding G et al. Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis - a GALEN study. Allergy 2009;64:520-33.
15. 2 LEN (Global Allergy and Asthma European Network) project. Allergy 2005;60:858-64.
16. 2LEN) a focus for paediatric allergy research. Pediatr Allergy Immunol 2006;17:163.
17. 2LEN The Global Allergy and Asthma European Network. Clin Exp Allergy 2005;35:122-5.
18. *Heinzerling L, Frew AJ, Bindslev-Jensen C, Bonini S, Bousquet J, Bresciani M et al. Standard skin prick testing and sensitization to inhalant allergens across Europe a survey from the GALEN network. Allergy 2005;60:1287-300.
19. 2LEN guideline. Allergy 2007;62:1111-8.
20. 2LEN position paper: present status of the atopy patch test. Allergy 2006;61:1377-84.
21. 2LEN. Allergy 2007;62:723-8.
22. 2)LEN. Allergy 2008;63:492-505.
23. 2LEN. Allergy 2008;63:387-403.
24. 2)LEN consensus report. Allergy 2007;62:683-94.
25. 2EN project. Allergy 2008;63:865-71.
26. 2LEN European case-control study. Eur Respir J 2008;32:1231-6.
27. *Keil T, Kulig M, Simpson A, Custovic A, Wickman M, Kull I et al. European birth color studies on asthma and atopic diseases: I. Comparison of study designs a GALEN initiative. Allergy 2006;61:221-8.
28. *Keil T, Kulig M, Simpson A, Custovic A, Wickman M, Kull I et al. European birth cohort studies on asthma and atopic diseases: II. Comparison of outcomes and exposures a GALEN initiative. Allergy 2006;61:1104-11.
29. 2LEN initiative. Allergy 2008;63:1491-8.
30. 2LEN review. Allergy 2008;63:47-57.
31. *Tricon S, Willers S, Smit H, Burney P, Devereux A, Frew A et al. Nutrition and allergic diseases. Clin Exp Rev 2006;6:117-88.
32. 2LEN and InterAirways document. Allergy 2007;62:457-70.
33. *Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008;205:2887-98.
34. Brunekreef B. Environmental epidemiology and risk assessment. Toxicol Lett 2008;180:118-22.
35. *Brunekreef B. Health effects of air pollution observed in cohort studies in Europe. J Expo Sci Environ Epidemiol 2007;17(Suppl 2):S61-5.
36. 2LEN study. Atmosph Environ 2007;41:7500-11.
37. *Aguilera I, Sunyer J, Fernandez-Patier R, Hoek G, Aguirre-Alfaro A, Meliefste K et al. Estimation of outdoor NO(x), NO(2), and BTEX exposure in a cohort of pregnant women using land use regression modeling. Environ Sci Technol 2008;42:815-21.
38. Kogevinas M, Zock JP, Jarvis D, Kromhout H, Lillienberg L, Plana E et al. Exposure to substances in the workplace and new-onset asthma: an international prospective population-based study (ECRHS-II). Lancet 2007;370:33641.
39. *Radon K, Gerhardinger U, Schulze A, Zock JP, Norback D, Toren K et al. Occupation and adult onset of rhinitis in the general population. Occup Environ Med 2008;65:38-43.
40. Medina-Ramon M, Zock JP, Kogevinas M, Sunyer J, Basagana X, Schwartz J et al. Short-term respiratory effects of cleaning exposures in female domestic cleaners. Eur Respir J 2006;27:1196-203.
41. Radon K, Huemmer S, Dressel H, Windstetter D, Weinmayr G, Weiland S et al. Do respiratory symptoms predict job choices in teenagers? Eur Respir J 2006;27:774-8.
42. Riu E, Dressel H, Windstetter D, Weinmayr G, Weiland S, Vogelberg C et al. First months of employment and new onset of rhinitis in adolescents. Eur Respir J 2007;30:549-55.
43. *Bousquet J, Anto JM, Bachert C, Bousquet PJ, Colombo P, Crameri R et al. Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GALEN project. Allergy 2006;61:671-80.
44. *Bousquet PJ, Chatzi L, Jarvis D, Burney P. Assessing skin prick tests reliability in ECRHS-I. Allergy 2008;63:341-6.
45. *Bousquet PJ, Hooper R, Kogevinas M, Jarvis D, Burney P. Number of allergens to be tested to assess allergenic sensitization in epidemiologic studies: results of the European Community Respiratory Health Survey I. Clin Exp Allergy 2007;37:780-7.
46. *Bousquet PJ, Leynaert B, Neukirch F, Sunyer J, Janson CM, Anto J et al. Geographical distribution of atopic rhinitis in the European Community Respiratory Health Survey I. Allergy 2008;63:1301-9.
47. *Watelet JB, Van Zele T, Gjomarkaj M, Canonica GW, Dahlen SE, Fokkens W et al. Tissue remodelling in upper airways: where is the link with lower airway remodelling? Allergy 2006;61:1249-58.
48. Gagliardo R, La-Grutta S, Chanez P, Profita M, Paterno A, Cibella F et al. Noninvasive markers of airway inflammation and remodeling in childhood asthma. Pediatr Allergy Immunol 2009 [In press].
49. Lang A, Carlsen KH, Haaland G, Devulapalli CS, Munthe-Kaas M, Mowinckel P et al. Severe asthma in childhood: assessed in 10 year olds in a birth cohort study. Allergy 2008;63:1054-60.
50. *Carlsen KH, Kowalski ML. Asthma, allergy, the athlete and the Olympics. Allergy 2008;63:383-6.
51. 2)LEN review. Allergy 2008;63:1015-30.
52. 2LEN review. Allergy 2008;63:660-9.
53. *Bousquet J, Zuberbier T, Mullol J, ACCEPT-1 Study Group icwGL. Improvement in disease specific quality of life and reduced symptom burden measured with a visual analogue scale in subjects with intermittent allergic rhinitsi treated with desloratadine. Allergy 2008;62(Suppl 64).
54. *Bousquet J, del-Carpio J, group AS. Improvement in disease-specific quality of life and reduced symptom burden measured with a visual analogue scale in subjects widi persistent allergic rhinitis treated with desloratadine. Seatde, WA: American College of Allergy, Asthma and Immunology; 2008.
55. Kabesch M. Gene by environment interactions and the development of asthma and allergy. Toxicol Lett 2006;162:43-8.
56. *Kauffmann F, Cambon-Thomsen A. Tracing biological collections: between books and clinical trials. JAMA 2008;299:2316-8.
57. *Passalacqua G, Bousquet PJ, Carlsen KH, Kemp J, Lockey RF, Niggemann B et al. ARIA update: I - Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol 2006;117:1054-62.
58. 2LEN. Allergy 2006;61:681-92.
59. 2)LEN. Allergy 2007;62(Suppl 84):1-41.
60. *Bousquet J, Bindslev-Jensen C, Canonica GW, Fokkens W, Kim H, Kowalski M et al. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy 2004;59(Suppl 77):4-16.
61. *Bousquet J, van Cauwenberge P, Ait Khaled N, Bachert C, Baena-Cagnani CE, Bouchard J et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GALEN). Allergy 2006;61:1086-96.
62. 2)LEN). Allergy 2005;60:1112-5.
63. *Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007;119:881-91.
64. van Weel C. General practitioners' central role in management of asthma and allergic rhinitis. Allergy 2008;63:1005-7.
65. *Ryan D, van Weel C, Bousquet J, Toskala E, Ahlstedt S, Palkonen S et al. Primary care: the cornerstone of diagnosis of allergic rhinitis. Allergy 2008;63:981-9.
66. *Bousquet J, Reid J, van Weel C, Baena Cagnani C, Canonica GW, Demoly P et al. Allergic rhinitis management pocket reference 2008. Allergy 2008;63:990-6.
67. 2)LEN and EAACI activities. Allergy 2006;61:1373-6.
68. 2LEN/EDF guideline: management of urticaria. Allergy 2006;61:321-31.
69. 2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006;61:316-20.
70. *Brozek JL, Baena-Cagnani CE, Bonini S, Canonica GW, Rasi G, van Wijk RG et al. Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy 2008;63:38-46.